Some efficient agents such as PD1 and EGFR specific antibodies4 and reversible tyrosine kinase inhibitors (TKIs) Gefitinib5 and Erlotinib6 benefit a proportion of NSCLC patients, but treatment with Gefitinib and Erlotinib will cause drug resistance for a period of time (6~12 months) . Here, EGFR is linked to non-small cell lung carcinoma.